GENERAL COMMENTS
This Editorial approaches very important factors associated to the current Evidence-based medicine (EBM) in the specific case of children, where many medicines are used in an off-label manner. The clear peer review process is also another important step approaching on this work. Finally, the Editorial proposes to request a Data sharing, the provision of the original research data for each scientific study, just to warrant a transparent and repeatable analysis.
The Editorial is sufficiently clear and complete. I would just suggest maybe going a little deeper into the idea that EBM also has to be critically analysed, when in some cases there may be some methodological problems and/or conflicts of interest. The human papilloma vaccine is a recent example of the hijacking of EBM. A Cochrane Review published in the year 2017 on this subject (1) generated several criticisms (2) that led to the need to carry out an update and complete review (3) of the included studies and the analyses carried out. 
Data sharing is a relevant topic for public health and medical research, and even more essential when trials involved vulnerable subjects, as children and adolescents. In my opinion, the editorial discusses the issue appropriately. I have no comments or suggestions.
VERSION 1 -AUTHOR RESPONSE
Thank you for the helpful comments. I have added an extra paragraph highlighting different opinions on interpretation of data. I have included the example of HPV vaccine as suggsted by the reviewer and also two other examples of different guidelines. Please let me know if you want further changes
